David W. Kaufman

David W. Kaufman

Auto-generated profile, based on publicly available information

David W. Kaufman

Slone Epidemiology Center at Boston University, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

51Years (1976-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2002 in JAMA
Verified
Journal Article
Open access
PDF file
DKDavid W. Kaufman
David W. Kaufman
JKJudith P. Kelly
Judith P. Kelly
LRLynn Rosenberg
Lynn Rosenberg
TATheresa E. Anderson
Theresa E. Anderson
AMAllen A. Mitchell
Allen A. Mitchell
A large number and wide variety of medications approved for use by the US Food and Drug Administration (FDA) are available to the US population, and expenditures on drugs have increased dramatically in recent years.1-3 New prescription drugs are continually introduced, and older drugs are increasingly available over the counter (OTC), making self-medication commonplace. Adverse reactions to drugs are among the leading causes of hospitalization and death in this country.4,5 At the same time, there has been a considerable increase in the use of herbal products and other natural supplements6,7 (henceforth referred to as "herbals/supplements"), which by law are not subject to FDA regulation. Although these products may be taken concurrently with regulated medications, health care professionals are often not informed of such use by their patients.7 Evidence is growing that many herbals/supplements have pharmacologic activity that can lead to clinically serious adverse interactions when they are taken together with regulated drugs,8 but there is little information available to estimate the potential magnitude of this problem.

1 November 1996 in The Lancet
Verified
Journal Article
Open access
JKJudith P Kelly
Judith P Kelly
DKDavid W Kaufman
David W Kaufman
JJJan M Jurgelon
Jan M Jurgelon
JSJane Sheehan
Jane Sheehan
RKRaymond S Koff
Raymond S Koff
SSSamuel Shapiro
Samuel Shapiro
Aspirin products are known to cause irritation and injury to the gastric mucosa. The belief that enteric-coated and buffered varieties are less likely to occasion major upper-gastrointestinal bleeding (UGIB) than plain aspirin was tested in data from a multicentre case-control study. 550 incident cases of UGIB admitted to hospital with melaena or haematemesis and confirmed by endoscopy, and 1202 controls identified from population census lists, were interviewed about use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) during the 7 days before the onset of bleeding (cases) or interview (controls). Relative risks of UGIB for each type of aspirin used regularly (at least every other day) were calculated overall, and according to dose, by multiple logistic regression, with control for age, sex, marital status, date, education, cigarette smoking, alcohol use, and use of NSAIDs. The relative risks of UGIB for plain, enteric-coated, and buffered aspirin at average daily doses of 325 mg or less were 2.6, 2.7, and 3.1, respectively. At doses greater than 325 mg, the relative risk was 5.8 for plain and 7.0 for buffered aspirin; there were insufficient data to evaluate enteric-coated aspirin at this dose level. There were no important differences in risk attributable to the three aspirin forms according to bleeding site (gastric vs duodenal), or when users of NSAIDs were excluded. Use of low doses of enteric-coated or buffered aspirin carries a three-fold increase in the risk of major UGIB. The assumption that these formulations are less harmful than plain aspirin may be mistaken.

12 December 1985 in New England Journal of Medicine
Verified
Journal Article
Closed access
LRLynn Rosenberg
Lynn Rosenberg
DKDavid W. Kaufman
David W. Kaufman
SHSusan P. Helmrich
Susan P. Helmrich
SSSamuel Shapiro
Samuel Shapiro
We assessed the effect of quitting cigarette smoking on the incidence of nonfatal myocardial infarction in men under the age of 55 in a case–control study of 1873 men with first episodes of myocardial infarction and 2775 controls. For "current" smokers (men who had smoked in the previous year) as compared with those who had never smoked, the estimated relative risk of myocardial infarction, adjusted for age, was 2.9 (95 per cent confidence interval, 2.4 to 3.4). Among exsmokers (those who had last smoked at least one year previously), the relative-risk estimate declined to a value close to unity for those who had abstained for at least two years; the estimate was 2.0 (1.1 to 3.8) for men who had abstained for 12 to 23 months, and the estimates were about 1.0 for men who had abstained for longer intervals. The results were unchanged by allowance for multiple potential confounding factors. A similar pattern was apparent among exsmokers who had smoked heavily for many years; among those predisposed to a myocardial infarction because of family history, hypertension, or other risk factors; and among those with no apparent predisposition. The results suggest that the risk of myocardial infarction in cigarette smokers decreases within a few years of quitting to a level similar to that in men who have never smoked. (N Engl J Med 1985; 313:1511–4.)

1 June 2008 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
DKDavid W. Kaufman
David W. Kaufman
JKJudith P. Kelly
Judith P. Kelly
GCGary C. Curhan
Gary C. Curhan
TATheresa E. Anderson
Theresa E. Anderson
SDStephen P. Dretler
Stephen P. Dretler
DCDavid R. Cave
David R. Cave
Most kidney stones are composed primarily of calcium oxalate. Oxalobacter formigenes is a Gram-negative, anaerobic bacterium that metabolizes oxalate in the intestinal tract and is present in a large proportion of the normal adult population. It was hypothesized that the absence of O. formigenes could lead to increased colonic absorption of oxalate, and the subsequent increase in urinary oxalate could favor the development of stones. To test this hypothesis, a case-control study involving 247 adult patients with recurrent calcium oxalate stones and 259 age-, gender-, and region-matched control subjects was performed. The prevalence of O. formigenes, determined by stool culture, was 17% among case patients and 38% among control subjects; on the basis of multivariate analysis controlling demographic factors, dietary oxalate, and antibiotic use, the odds ratio for colonization was 0.3 (95% confidence interval 0.2 to 0.5). The inverse association was consistently present within strata of age, gender, race/ethnicity, region, and antibiotic use. Among the subset of participants who completed a 24-h urine collection, the risk for kidney stones was directly proportional to urinary oxalate, but when urinary factors were included in the multivariable model, the odds ratio for O. formigenes remained 0.3 (95% confidence interval 0.1 to 0.7). Surprisingly, median urinary oxalate excretion did not differ with the presence or absence of O. formigenes colonization. In conclusion, these results suggest that colonization with O. formigenes is associated with a 70% reduction in the risk for being a recurrent calcium oxalate stone former.

15 September 2008 in Pain
Verified
Journal Article
Closed access
JKJudith Parsells Kelly
Judith Parsells Kelly
SCSuzanne F. Cook
Suzanne F. Cook
DKDavid W. Kaufman
David W. Kaufman
TATheresa Anderson
Theresa Anderson
LRLynn Rosenberg
Lynn Rosenberg
AMAllen A. Mitchell
Allen A. Mitchell
This report describes the prevalence of opioid use in the US adult population, overall and in subgroups, the characteristics of opioid use, and concomitant medication use among opioid users. Data were obtained from the Slone Survey, a population-based random-digit dialing survey. One household member was randomly selected to answer a series of questions regarding all medications taken during the previous week. There were 19,150 subjects aged > or = 18 interviewed from 1998 to 2006. Opioids were used 'regularly' ( > or = 5 days per week for > or = 4 weeks) by 2.0%; an additional 2.9% used opioids less frequently. Regular opioid use increased with age, decreased with education level, and was more common in females and in non-Hispanic whites. The prevalence of regular opioid use increased over time and was highest in the South Central region. Nearly one-fifth of regular users had been taking opioids for > or = 5 years. Concomitant use of > or = 10 non-opioid medications was reported by 21% of regular opioid users compared to 4.5% of subjects who did not use opioids. Regular opioid users were more likely to use stool softeners/laxatives (9% vs. 2%), proton pump inhibitors (25% vs. 8%), and antidepressants (35% vs. 10%). From this nationally-representative telephone survey, we estimate that over 4.3 million US adults are taking opioids regularly in any given week. Information on the prevalence and characteristics of use is important as opioids are one of the most widely prescribed classes of drugs in the US.

1 September 2002 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
NNNancy J Newman
Nancy J Newman
RSRoberta Scherer
Roberta Scherer
PLPatricia Langenberg
Patricia Langenberg
SKShalom Kelman
Shalom Kelman
SFSteven Feldon
Steven Feldon
KDKay Dickersin
Kay Dickersin